SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Castagnoli P)
 

Search: WFRF:(Castagnoli P) > Autoantibodies agai...

  • Zhang, Q (author)

Autoantibodies against type I IFNs in patients with critical influenza pneumonia

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2022-09-16
  • Rockefeller University Press,2022

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:151316233
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:151316233URI
  • https://doi.org/10.1084/jem.20220514DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10−5), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10−5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10−10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Pizzorno, A (author)
  • Miorin, L (author)
  • Bastard, P (author)
  • Gervais, A (author)
  • Le Voyer, T (author)
  • Bizien, L (author)
  • Manry, J (author)
  • Rosain, J (author)
  • Philippot, Q (author)
  • Goavec, K (author)
  • Padey, B (author)
  • Cupic, A (author)
  • Laurent, E (author)
  • Saker, K (author)
  • Vanker, M (author)
  • Sarekannu, K (author)
  • Garcia-Salum, T (author)
  • Ferres, M (author)
  • Le Corre, N (author)
  • Sanchez-Cespedes, J (author)
  • Balsera-Manzanero, M (author)
  • Carratala, J (author)
  • Retamar-Gentil, P (author)
  • Abelenda-Alonso, G (author)
  • Valiente, A (author)
  • Tiberghien, P (author)
  • Zins, M (author)
  • Debette, S (author)
  • Meyts, I (author)
  • Haerynck, F (author)
  • Castagnoli, R (author)
  • Notarangelo, LD (author)
  • Gonzalez-Granado, LI (author)
  • Dominguez-Pinilla, N (author)
  • Andreakos, E (author)
  • Triantafyllia, V (author)
  • Rodriguez-Gallego, C (author)
  • Sole-Violan, J (author)
  • Ruiz-Hernandez, JJ (author)
  • Rodriguez de Castro, F (author)
  • Ferreres, J (author)
  • Briones, M (author)
  • Wauters, J (author)
  • Vanderbeke, L (author)
  • Feys, S (author)
  • Kuo, CY (author)
  • Lei, WT (author)
  • Ku, CL (author)
  • Tal, G (author)
  • Etzioni, A (author)
  • Hanna, S (author)
  • Fournet, T (author)
  • Casalegno, JS (author)
  • Queromes, G (author)
  • Argaud, L (author)
  • Javouhey, E (author)
  • Rosa-Calatrava, M (author)
  • Cordero, E (author)
  • Aydillo, T (author)
  • Medina, RA (author)
  • Kisand, K (author)
  • Puel, A (author)
  • Jouanguy, E (author)
  • Abel, L (author)
  • Cobat, A (author)
  • Trouillet-Assant, S (author)
  • Garcia-Sastre, A (author)
  • Casanova, JL (author)

Related titles

  • In:The Journal of experimental medicine: Rockefeller University Press219:111540-95380022-1007

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view